Proportion of participants in which at least 1 conduction block resolved after therapy · people with multifocal motor neuropathy
IVIg showed no clear difference in proportion of participants in which at least 1 conduction block… compared with placebo (low certainty).
1 finding from 1 review
RR 7 [0.95, 51.7]
28 participants
Low
Maintenance · people with multifocal motor neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of IVIg‐treated participants with an increase in disability during controlled IVIg withdrawal · people with multifocal motor neuropathy
IVIg probably leads to higher proportion of IVIg‐treated participants with an increase in… compared with placebo (moderate certainty).
1 finding from 1 review
RR 2.43 [1.13, 5.24]
42 participants
Moderate
Proportion of IVIg‐treated participants with a decrease in muscle strength during controlled IVIg withdrawal · people with multifocal motor neuropathy
IVIg probably leads to lower proportion of IVIg‐treated participants with a decrease in muscle… compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.2 [0.07, 0.54]
42 participants
Moderate
Proportion of participants with side effects attributable to treatment · people with multifocal motor neuropathy
It is very uncertain whether IVIg changes proportion of participants with side effects attributable to treatment compared with placebo (very low certainty).
1 finding from 1 review
RR 10.33 [2.15, 49.77]
21 participants
Very low
Participant‐reported improvement in sialorrhea in the short term · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
Botulinum toxin injection showed no clear difference in participant‐reported improvement in sialorrhea in the short term… compared with placebo (low certainty).
1 finding from 1 review
Reduction in the amount of saliva production in the short term using an objective measure · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
no estimate extracted
1 participants
Very low
Quality of life · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
no estimate extracted
1 participants
Moderate
Participant‐reported improvement in sialorrhea in the short term · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…
1 finding from 1 review
no estimate extracted
8 participants
Very low
Reduction in the amount of saliva production in the short term using an objective measure · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…
1 finding from 1 review
no estimate extracted
8 participants
Very low
Quality of life · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with motor neuron disease/amyotrophic lateral sclerosis with sialorrhea (excessive saliva) (all fed via gastrostomy and most…
1 finding from 1 review
no estimate extracted
10 participants
Very low
Reduction in the amount of saliva production in the short term using an objective measure · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
Health‐related quality of life Assessed by: SeiQoL‐DW (higher scores mean better quality of life) · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
Adverse effects · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
Botulinum toxin injection may leads to lower adverse effects compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported improvement in sialorrhea in the short term · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
no estimate extracted
1 participants
Moderate
Change in cramp severity (0 to 10 VAS; higher = worse pain) (after 6 weeks) · older adults with lower limb muscle cramps
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants experiencing cramps · older adults with lower limb muscle cramps
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · older adults with lower limb muscle cramps
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found